Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Aug;11(8):2926-2930.
doi: 10.21037/tcr-22-33.

Male triple negative axillary accessory breast cancer-a case report

Chao Li  1   2 , Biao Qian  1   2
Affiliations
Case Reports

Male triple negative axillary accessory breast cancer-a case report

Chao Li et al. Transl Cancer Res. 2022 Aug.

Abstract

Background: Breast cancer is the most common malignancy among women worldwide. In men, cases of breast cancer are few and account for less than 1% of all cases of breast cancer. Majority of male breast cancer is hormone receptor-positive. The incidence of male breast cancer derived from axillary accessory breast is very low. Here we report a case of male triple negative axillary accessory breast cancer.

Case description: We present a case of male triple negative axillary accessory breast cancer in a 67-year-old man, which progressively increased in size through a period of 1 year. Ultrasound examination showed a 31 mm × 17 mm mass in the right axillary tail region with some accessory breast tissue around. We performed right accessory breast resection and right axillary lymph nodes dissection. Postoperative pathological analysis revealed right accessory breast invasive ductal carcinoma with apocrine metaplasia. The tumor size was 3.5 cm × 3.3 cm. In addition, 5 metastatic lymph nodes were seen in 27 axillary lymph nodes. Immunohistochemistry showed estrogen-receptor (ER) (-), progesterone-receptor (PR) (-), human epidermal growth factor receptor 2 (HER2) (2+). Fluorescence in situ hybridization (FISH) test obtained a negative result. The patient was treated with adjuvant chemotherapy and radiotherapy. Until now, no obvious signs of recurrence or metastasis have been observed during regular follow-ups.

Conclusions: Male triple negative axillary accessory breast cancer is rare. Treatment of male triple negative axillary accessory breast cancer is similar to that of women. Most patients undergo surgery and adjuvant chemotherapy.

Keywords: Male breast cancer; accessory breast cancer; case report; triple negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-33/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Ultrasound examination showed a 31 mm × 17 mm mass in the right axillary accessory breast.
Figure 2
Figure 2
Ultrasound examination showed an enlarged axillary lymph node.
Figure 3
Figure 3
Postoperative pathological analysis revealed right accessory breast invasive ductal carcinoma with apocrine metaplasia in Hematoxylin Eosin staining (HE ×400), HE, Hematoxylin Eosin staining.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49. 10.3322/caac.21660 - DOI - PubMed
    1. Fox S, Speirs V, Shaaban AM. Male breast cancer: an update. Virchows Arch 2022;480:85-93. 10.1007/s00428-021-03190-7 - DOI - PubMed
    1. Serdy KM, Leone JP, Dabbs DJ, et al. Male Breast Cancer. Am J Clin Pathol 2017;147:110-9. - PubMed
    1. Liu N, Johnson KJ, Ma CX. Male Breast Cancer: An Updated Surveillance, Epidemiology, and End Results Data Analysis. Clin Breast Cancer 2018;18:e997-e1002. 10.1016/j.clbc.2018.06.013 - DOI - PubMed
    1. Bi M, Li D, Su Y, et al. Male axillary accessory breast cancer: A case report. Medicine (Baltimore) 2020;99:e19506. 10.1097/MD.0000000000019506 - DOI - PMC - PubMed

Publication types